AMY CALICE: Open Payments
NPI 1033605183 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,392 in 74 payments from 22 companies in 2025. Trend: 2023 $2,189 · 2024 $1,827 · 2025 $1,392
Food & beverage: $1,392
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $596 |
| AstraZeneca Pharmaceuticals LP | 3 | $138 |
| Lilly USA, LLC | 5 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $67 |
| Sumitomo Pharma America, Inc. | 3 | $66 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $64 |
| Novo Nordisk Inc | 3 | $47 |
| Astellas Pharma US Inc | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
Products named: VRAYLAR, QULIPTA, FARXIGA, UBRELVY, MOUNJARO, CAPLYTA, GEMTESA, JARDIANCE.
Industry payments across MO — which companies pay providers there.
